- Home
- SGLY vs RDHL Comparison
SGLY vs RDHL Comparison
Compare SGLY & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGLY
- RDHL
- Stock Information
- Founded
- SGLY 2001
- RDHL 2009
- Country
- SGLY United States
- RDHL Israel
- Employees
- SGLY N/A
- RDHL N/A
- Industry
- SGLY
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- SGLY
- RDHL Health Care
- Exchange
- SGLY Nasdaq
- RDHL Nasdaq
- Market Cap
- SGLY 3.4M
- RDHL 3.9M
- IPO Year
- SGLY 2008
- RDHL N/A
- Fundamental
- Price
- SGLY $0.59
- RDHL $1.05
- Analyst Decision
- SGLY
- RDHL
- Analyst Count
- SGLY 0
- RDHL 0
- Target Price
- SGLY N/A
- RDHL N/A
- AVG Volume (30 Days)
- SGLY 183.2K
- RDHL 1.5M
- Earning Date
- SGLY 11-14-2025
- RDHL 09-05-2025
- Dividend Yield
- SGLY N/A
- RDHL N/A
- EPS Growth
- SGLY N/A
- RDHL N/A
- EPS
- SGLY N/A
- RDHL N/A
- Revenue
- SGLY $1,619,679.00
- RDHL $9,550,000.00
- Revenue This Year
- SGLY N/A
- RDHL $381.91
- Revenue Next Year
- SGLY N/A
- RDHL N/A
- P/E Ratio
- SGLY N/A
- RDHL N/A
- Revenue Growth
- SGLY N/A
- RDHL 157.62
- 52 Week Low
- SGLY $0.54
- RDHL $1.01
- 52 Week High
- SGLY $5.49
- RDHL $8.75
- Technical
- Relative Strength Index (RSI)
- SGLY 42.61
- RDHL 34.47
- Support Level
- SGLY $0.55
- RDHL $1.01
- Resistance Level
- SGLY $0.65
- RDHL $1.07
- Average True Range (ATR)
- SGLY 0.09
- RDHL 0.12
- MACD
- SGLY 0.01
- RDHL 0.01
- Stochastic Oscillator
- SGLY 15.00
- RDHL 8.47
About SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.